CA
NZ
UK
AU
IND
US
• The company filed the update with the U.S. Securities and Exchange Commission.
• No significant difference in mortality rates was observed between Vafseo and ESA, with rates of 8.77% and 8.78% per 100 patient years, respectively.
• Allarity Therapeutics reported 8,364,272 shares, representing 54.10% voting presence at its annual shareholder meeting.
• Allurion Technologies (NYSE: ALUR) director R. Jason Richey resigned as audit committee chair effective June 24, 2026.
• Accelerated Buyback: Novo Nordisk (NYSE: NVO) accelerated its DKK 15 billion share buyback programme, returning capital to shareholders.
• Mixed Q1 Results: Royalty Pharma (NASDAQ: RPRX) beat on EPS at $1.30 but revenue of $630.6 million badly missed the $881.7 million consensus.
• Sharp Outperformance: Hims & Hers (NYSE: HIMS) is sharply beating a flat XLV and a modestly higher S&P 500 on the first day of H2 2026.
• Margins Take Center Stage: After a Q1 EPS miss, margin recovery has become the key focus for TransMedics (NASDAQ: TMDX) investors.
• Device Makers Lag: Boston Scientific (NYSE: BSX) sits near 52-week lows and Medtronic (NYSE: MDT) fell on weak guidance, diverging from a strong sector.
• Canaccord Reaffirms Buy: Canaccord Genuity maintained its Buy rating with a $124 price target, implying significant upside from depressed levels.
Please wait processing your request...